Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients

A. Leone, M. Correale, C. D. Dragone, A. Paradiso, M. De Lena, W. G. Stetler-Stevenson, L. A. Liotta, L. Masiero, S. Garbisa

Research output: Contribution to journalArticlepeer-review


The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collagenase, MMP-2). In an effort to assess the significance of these findings to breast cancer progression, we have evaluated the gelatinase A/MMP-2 serum levels in a cohort of 80 breast cancer patients, 27 subjects affected by benign breast disease and 27 healthy controls. Although differences between the three groups were observed, with the highest values monitored in benign breast disease, they were not statistically significant. On the contrary, within the breast cancer cohort, the patients presenting clinical evidence of distant metastases (M+, n=40) had statistically elevated enzyme serum levels (p

Original languageEnglish
Pages (from-to)551-554
Number of pages4
JournalInternational Journal of Oncology
Issue number3
Publication statusPublished - 1994


  • breast cancer
  • gelatinase A
  • metastases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients'. Together they form a unique fingerprint.

Cite this